Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

British journal of haematology - 1 Feb 2019

Eyre Toby A, Fox Christopher P, Boden Ali, Bloor Adrian, Dungawalla Moez, Shankara Paneesha, Went Richard, Schuh Anna H

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Mutation
Share to Purines
Share to Quinazolinones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Remission Induction

Share to Rituximab

Share to Tumor Suppressor Protein p53

Share to United Kingdom

Source

Identifiers

PMID: 29468637
DOI: 10.1111/bjh.15151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.PMID 29468637Read ↗

Lymphoma: turning biology into cures.Semantic proximity Read ↗

Your chemo is no good here: management of high-risk MCL.Semantic proximity Read ↗

The treatment of Burkitt lymphoma in adults.Semantic proximity Read ↗

Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read ↗

Single-Cell Analysis Reveals Ide-cel and Cilta-cel Characteristics That Influence EfficacySemantic proximity Read ↗

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.Semantic proximity Read ↗

Development of molecular intervention strategies for B-cell lymphoma.Semantic proximity Read ↗

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Semantic proximity Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.